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Abstract 
 
Background: Colonization by Aspergillus fumigatus (Af) in cystic fibrosis (CF) may 
cause Af sensitization and/or allergic bronchopulmonary aspergillosis (ABPA) which 
affects pulmonary function and clinical outcomes. Recent studies show that specific 
allergens upregulate the surface-expressed basophil marker CD203c in sensitized 
individuals, a response that can be readily measured by flow cytometry.  
Objective: To identify Af-sensitization in CF using the basophil activation test (BAT).  
Methods: Patients with CF attending Beaumont Hospital were screened for study 
inclusion. BAT was used to identify Af sensitization. Serologic (total IgE and Af-
specific IgE), pulmonary function and body mass index measurements were 
performed.  
Results: The BAT discriminates Af-sensitized from non-sensitized patients with CF. 
Persistent isolation of Af in sputum is a significant risk factor for Af sensitization. 
Levels of the Af-stimulated basophil activation marker, CD203c, inversely correlated 
with pulmonary function and body mass index in Af-sensitized but not non-sensitized 
patients with CF. Total and Af-specific IgE, but not IgG, are elevated in Af-sensitized 
CF patients with ABPA when compared to Af-sensitized and non-sensitized CF 
patients without ABPA. Itraconazole treatment did not affect Af sensitization.  
Conclusion: Combining the BAT with routine serological testing allows classification 
of patients with CF into three groups: non-sensitized, Af-sensitized and ABPA. 
Accurate and prompt identification of Af-associated clinical status may allow early 
and targeted therapeutic intervention potentially improving clinical outcomes. 
 
 
 
Key Messages 
 The basophil activation test can identify Aspergillus fumigatus-sensitized 
individuals in the cystic fibrosis population. 
 CD203c levels inversely correlate with pulmonary function and body mass index 
in A. fumigatus-sensitized people with cystic fibrosis.  
 Prompt identification of A. fumigatus sensitization may improve the management 
of A. fumigatus-associated disease in cystic fibrosis. 
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Capsule Summary 
This study demonstrates a novel means of identifying A. fumigatus sensitization in 
cystic fibrosis using the basophil activation test. Simpler classification of Aspergillus–
associated disease will likely improve both clinical management and outcomes.  
 
Keywords: allergic bronchopulmonary aspergillosis; Aspergillus fumigatus; basophil 
activation test; body mass index; CD203c; cystic fibrosis; flow cytometry; forced 
expiratory volume in the first second; itraconazole; sensitization. 
 
Abbreviations:  
ABPA: allergic bronchopulmonary aspergillosis 
Af: Aspergillus fumigatus 
BAT: basophil activation test 
BMI: body mass index 
CF: cystic fibrosis 
EDTA: ethylenediaminetetraacetic acid 
FEV1: forced expiratory volume in the first second 
GM: galactomannan 
MFI: mean fluorescence intensity 
PWCF: people with CF 
ROC: receiver-operating characteristic 
sIgE: specific IgE 
sIgG: specific IgG 
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INTRODUCTION 
Cystic fibrosis (CF) is an inherited disorder characterized by recurrent polymicrobial 
pulmonary exacerbations and chronic neutrophil-dominated inflammation. 
Dysfunctional CFTR protein leads to impaired mucociliary clearance and colonization 
of the CF lung by bacteria and fungi. Much focus has been given to the role of 
bacteria in the CF airway; however, an increasing recognition of fungi has emerged.1–
3 Aspergillus fumigatus (Af) is the most commonly isolated fungus in CF with a 
prevalence of up to 60%.4 The fungus is associated with a range of manifestations in 
CF, most commonly allergic bronchopulmonary aspergillosis (ABPA) and less 
commonly, aspergillomas and invasive pulmonary aspergillosis.5–7  
ABPA affects between 2%-15% of patients with CF (PWCF) and recurrent episodes 
impact pulmonary function.1,8–11 It manifests as an allergic, hypersensitive, Th2 CD4+ 
cell-driven response to Af and the diagnosis of ABPA in CF is particularly challenging 
due to overlapping clinical, immunological and radiological features that are similar to 
those of a pulmonary exacerbation. To address this, consensus conference criteria 
were published to aid clinicians in diagnosing CF-ABPA.12 Despite this, inherent 
weaknesses in these criteria exist. They can be difficult to employ in the CF setting 
and many CF patients with ABPA do not fulfill these criteria despite a good response 
to treatment. The criteria have not been updated for 12 years despite advances in 
both the understanding and the treatment of CF-ABPA. Hence, there is a growing 
need for a simplified, updated classification to robustly diagnose ABPA, facilitating 
earlier intervention to improve clinical outcome.  
Sensitization is an immunological phenomenon, defined by the production of specific 
IgE (sIgE). It can arise from a combination of genetic predisposition and allergen 
exposure.13,14 Recent reports show that Af sensitization is associated with a greater 
decline in lung function and an increased rate of pulmonary exacerbations in CF.15–17 
The basophil activation test (BAT) is a novel technique that measures upregulation of 
CD203c upon stimulation with the specific allergen to which an individual is 
sensitized.18 CD203c is an ectonucleotide pyrophosphatase/phosphodiesterase 
expressed on the surface of basophils, which are important effector cells in type II 
immune responses.18,19 CD203c can be rapidly measured by flow cytometry and has 
been proposed as a diagnostic tool in atopic disease, including peanut, drug and 
wasp venom allergy.20–22  
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It has been shown that basophils are primed and hyper-responsive to Af allergen 
stimulation in CF-ABPA.18 In this current study, BAT to Af was employed to identify Af 
sensitization in a CF cohort and it was correlated with key CF clinical measurements. 
Furthermore, Af-stimulated CD203c, in conjunction with commonly available 
immunological parameters, was examined for use in the classification of patients with 
CF into non-sensitized, sensitized or ABPA groups.  
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METHODS 
 
Patient recruitment 
We prospectively recruited 48 PWCF to the study between October 2012 and 
October 2014. As controls, 11 healthy non-CF volunteers were also recruited. Ethical 
approval was obtained from our Institutional Review Board. CF was confirmed by 
sweat chloride levels (>60 mmol/L) and genotyping. Pulmonary function testing 
(Online Supplement) and serum sampling was performed on the day of the BAT. 
Total circulating IgE, sIgE and specific IgG (sIgG) levels to Af were determined using 
the ImmunoCap assay (Phadia, Uppsala, Sweden). Patient demographics are 
outlined in Supporting Table EI. Quarterly sputum samples were routinely collected 
for standard microbiological evaluation, including fungi.23 Exclusion criteria were 
pregnancy, lung transplantation, peanut allergy and those under 16 years of age. 
  
Cohort characterization 
The CF-ABPA cohort was diagnosed as per previously published consensus criteria. 
Specific IgE (sIgE) levels to Aspergillus were used as an alternative to skin prick 
testing that are  interchangeable in consensus criteria.12 To differentiate between Af-
sensitized and non-sensitized CF individuals, an arbitrary cut-off (1.36) was set at 
three standard deviations above the mean value24 of the stimulation index of the 
healthy control population, with the stimulation index defined as the ratio between Af- 
and PBS-stimulated CD203c values.  
  
Basophil activation test 
Samples were processed as previously described.18,25,26 Briefly, venous blood was 
collected in S-Monovette® ethylenediaminetetraacetic acid (EDTA) blood tubes 
(Sarstedt, Germany) and centrifuged at 400g for 10 min at 4 °C. The supernatant 
was further centrifuged at 3000g for 10 min at 4 °C and 97 µl of platelet-free plasma 
was added to 100 µl of erythrocyte/leukocyte pellet and incubated for 30 s at 37 °C. 
Samples were incubated with 3 μl Af extract (Mediwiss Analytic GmbH, Moers, 
Germany) for 10 min at 37 °C. PBS and peanut extract (Mediwiss) were used as 
controls. Untreated basophils were also evaluated. After washing, cells were stained 
with FITC mouse anti-human CD3, HLA-DR, CD41a, and CD66b, PerCP-Cy5.5 
mouse anti-human CD123 (BD Biosciences, San Jose, CA) and PE mouse anti-
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human CD203c (Biolegend, San Diego, CA) at saturating concentrations. 
LIVE/DEAD® FixableNear-IR Dead Cell stain kit (Invitrogen, Carlsbad, CA) was used 
to distinguish between live and dead cells. After washing, erythrocytes were lysed 
and leukocytes were fixed with Lyse/Fix buffer (BD Biosciences) for 30 min on ice. 
After centrifugation at 490g for 5 min, cells were resuspended in 2.5 mM EDTA 
containing 5 % FCS and analyzed by flow cytometry on a BD FACSCalibur (BD 
Biosciences) equipped with BD CellQuest Pro Software. Compensation was 
performed using CaliBRITE Beads (BD Biosciences) and at least 200 basophils per 
sample were analyzed. Data were analyzed using FlowJo software (Ashland, OR).  
 
Statistical Analysis 
Statistical analysis was performed using GraphPad PRISM 4.0 (San Diego, CA). 
Data were tested for normality using the Kolmogorov-Smirnoff test. Normal data were 
compared using a two-tailed independent Student’s t-test and for non-normal data, 
the Mann-Whitney U test was performed. Differences were considered significant at 
P < 0.05. 
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RESULTS 
 
Basophil activation test discriminates between non-sensitized and Af-
sensitized patients with CF  
Flow cytometry was used to measure basophil activation in response to Af. Basophils 
were gated as the Live/Dead−/CD3−/HLA-DR−/CD41a−/CD66b−/CD123+ population 
and evaluated for CD203c expression following Af extract stimulation (Supporting 
Figure E1). PBS and peanut extract were used as non-offending and immunogenic 
controls, respectively. To differentiate between Af-sensitized and non-sensitized 
PWCF, an arbitrary cut-off of 1.36 was determined using the stimulation index of the 
non-CF controls (mean ± SD = 1.018 ± 0.114; n = 11). A positivity threshold of three 
standard deviations above the healthy mean of the stimulation index was determined 
as before.24 Using this cut-off, 23 (47.9%) of the 48 recruited PWCF were Af-
sensitized. The ability of sIgE to distinguish between sensitized and non-sensitized 
individuals has been previously proposed using a cut-off of 0.35 kU/L.16 The 
diagnostic performance of the BAT was examined against sensitization status 
determined with sIgE (Af sensitization cut-off 0.35 kU/L; ImmunoCap assay)16 using 
receiver-operating characteristic (ROC)-curve analyses. The area under the ROC 
curve was 0.9134 (P < 0.0001; Supporting Figure E2) indicating the excellent 
discriminating ability of the BAT between non-sensitized and Af-sensitized PWCF 
and corroborating the strength of Af-stimulated CD203c levels as an indicator of Af 
sensitization in CF. 
 
Af-sensitized PWCF have higher frequency of Af-positive sputum cultures 
compared to non-sensitized PWCF  
Patients with CF were screened for the presence of Aspergillus spp. in their quarterly 
sputum samples as part of routine care, amounting to eight sputum samples from 
each patient in the two year period preceding the BAT. Fourteen out of 23 (60.9%) 
Af-sensitized patients, but only 6 out of 25 (24.0 %) non-sensitized PWCF, grew Af 
on at least one occasion in the 2-year period preceding the BAT. Af-sensitized PWCF 
displayed higher frequency of Af sputum isolation compared to non-sensitized PWCF 
(P = 0.0038; Figure 1). To verify the specificity of the BAT to Af, Candida albicans 
colonization was also assessed. In contrast to Af, 19 out of 23 (82.6%) Af-sensitized 
and 17 out of 25 (68.0 %) non-sensitized PWCF grew C. albicans at least once in the 
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2 years preceding the BAT. There was no significant difference in the frequency of C. 
albicans isolation between groups (Supporting Figure E3), illustrating the specificity 
of the BAT to Af. Similar results were observed when colonization with Pseudomonas 
aeruginosa was investigated (Supporting Figure E4). No significant difference in Af-
stimulated CD203c levels between patients with non-mucoid (P = 0.3263) or mucoid 
P. aeruginosa (P = 0.2351) compared with their non-colonized counterparts was 
noted. In summary, BAT to Af is specific and PWCF with increased frequency of Af in 
sputum are more likely to develop sensitization to Af. 
 
Af-stimulated CD203c levels are increased in blood basophils from Af-
sensitized compared to non-sensitized PWCF 
Af-sensitized PWCF had significantly higher Af-stimulated CD203c values compared 
to healthy controls (P < 0.0001) and non-sensitized PWCF (P < 0.0001; Figure 2A). 
Interestingly, Af-stimulated CD203c values were significantly higher in Af-sensitized 
PWCF with ABPA than Af-sensitized CF individuals without ABPA (P = 0.0408; 
Figure 2B). This demonstrates that the BAT to Af distinguishes Af-sensitization from 
non-sensitization along a quantitative spectrum and could also be potentially used in 
the diagnosis of individuals with ABPA within the Af-sensitized cohort. 
 
CD203c expression levels inversely correlate with FEV1 and BMI of Af-
sensitized PWCF 
Af sensitization has previously been shown to be associated with worse lung function 
in a variety of pulmonary diseases, including asthma, chronic obstructive pulmonary 
disease and CF.16,17,27,28 We therefore explored the relationship of Af-stimulated 
CD203c levels with lung function (forced expiratory volume in the first second, FEV1) 
and body mass index (BMI), both established determinants of mortality in CF.29 We 
observed a significant correlation of Af-stimulated CD203c levels with declining FEV1 
in Af-sensitized patients (n = 16, r2 = 0.6409, P = 0.0002; Figure 3A). Interestingly, no 
correlation between Af-stimulated CD203c values and FEV1 in non-sensitized PWCF 
was detected (n = 25, r2 = 0.0198, P=0.5027; Figure 3A). CF-ABPA patients 
receiving corticosteroid treatment were excluded from this analysis due to the 
potential interference of corticosteroid therapy with CD203c levels (see Supporting 
Figure E5 and E6). BMI was also shown to inversely correlate with Af-stimulated 
CD203c levels in Af-sensitized (n = 16, r2= 0.3009, P = 0.0278) but not non-
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sensitized PWCF (n = 25, r2= 0.0905, P = 0.1439; Figure 3B). Together, these data 
illustrate that Af-stimulated CD203c levels correlate with key clinical parameters in 
CF, including FEV1 and BMI, confirming the clinical impact of the Af-sensitized state. 
 
Total IgE and Af-specific IgE, but not Af-specific IgG levels, are elevated in 
serum of Af-sensitized patients with ABPA 
Total IgE, Af sIgE and sIgG levels were evaluated in serum samples from non-
sensitized, Af-sensitized and CF patients with ABPA. As described above, the 
stimulation index threshold was used to distinguish sensitized (> 1.36) from non-
sensitized (< 1.36) individuals. The CF-ABPA individuals were defined as those 
meeting classical consensus criteria for ABPA.12 Total IgE levels were significantly 
higher in CF-ABPA (n = 7) when compared to non-sensitized and Af-sensitized 
PWCF (n = 25, P < 0.0001 and n = 16, P < 0.0001, respectively; Figure 4A). 
Similarly, when sIgE was assessed, significantly higher levels were observed in CF-
ABPA than in non-sensitized and Af-sensitized patients with CF (P = 0.0004 and P < 
0.0001, respectively; Figure 4B). Af-sensitized PWCF without ABPA had higher sIgE 
levels than non-sensitized PWCF (P <0.0001). No increase in sIgG levels were 
observed in the CF-ABPA group when compared to Af-sensitized and non-sensitized 
patients with CF; however, Af-sensitized PWCF without ABPA had higher sIgG levels 
than non-sensitized PWCF (P = 0.0302; Figure 4C). Therefore, total serum IgE and 
sIgE, but not sIgG, are useful in aiding the detection of CF-ABPA in CF and in 
differentiating it from Af-sensitization. 
 
Antifungal therapy does not alter Af-stimulated CD203c expression levels on 
basophils 
Recent work by our group has shown that elimination of Af bioburden with 
itraconazole (400 mg daily for 6 weeks) improves clinical outcome.23 To investigate 
the effect of fungal eradication on Af sensitization, BAT to Af was performed. 
Although we have previously shown that itraconazole reduces the fungal load in 
sputum,23 no change to CD203c levels pre- and post itraconazole treatment was 
observed (n = 8, P = 0.4028; Figure 5). Additionally, no difference in baseline 
CD203c expression was observed (n = 8, P = 0.3829; Supporting Figure E5A). This 
shows that decreasing the fungal burden in patients with CF undergoing anti-fungal 
therapy with itraconazole does not affect Af sensitization, once it is established. 
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Additionally, in a small number of patients (n = 4) receiving monthly pulses of high 
dose intravenous methylprednisolone for ABPA (10-15 mg/kg for three days),30 a 
trend towards efficacy of treatment was observed with Af-stimulated CD203c values 
halving (57.6%) one week after treatment initiation (P = 0.1604, Supporting Figure 
E6). This trend however decreased to 30% after one month, and prior to the next 
infusion of corticosteroids (n = 4, P = 0.2672; Supporting Figure E6), suggestive of 
the transient effect of corticosteroid therapy with time. 
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DISCUSSION 
The role of bacteria in the CF lung has been extensively studied and potential roles 
for fungi are beginning to emerge. Recently, much focus has been given to the wide 
spectrum of Af-associated morbidities in CF, including Af sensitization and ABPA. 
Both of these clinical states are associated with poorer clinical outcomes.16,31 For this 
reason, identifying individuals with Af sensitization with or without ABPA is important 
to ensure appropriate and timely therapeutic intervention to minimize pulmonary 
impact.30 In this study we focused on the basophil activation marker CD203c as an 
indicator of Af sensitization and assessed its effect on important clinical measures of 
CF disease. 
Sensitization to Af has previously been associated with poorer lung function,16,17 a 
finding further confirmed by this study. Gernez et al.18 recently reported that 
basophils from CF-ABPA patients are primed and hyper-responsive to stimulation 
with Af extract. In the current study, we employed the BAT to identify the Af 
sensitization status of our CF cohort. From a logistical viewpoint, the BAT to Af can 
be performed in under 4 hours using a maximum of 2 ml of whole blood. This can be 
taken in the same blood draw as the routinely measured immunological 
investigations minimizing discomfort for the patient. A flow cytometer and 
appropriately trained staff are required to perform the BAT, which would represent 
the only limitations to its applicability in routine CF centre practice. 
Almost half of the patients studied were Af-sensitized, which is in accordance with 
previous studies (31-61%) that employed serology and skin prick testing (SPT) 
alone.15–17 Elevated serum IgE to Af and SPTs are considered the gold standards for 
routine laboratory investigations and are part of the established consensus criteria for 
the diagnosis of ABPA in CF.12 Nevertheless, both of these tests harbour 
disadvantages. Specific IgE to Af is an easily accessible test for the clinician and is 
convenient for the patient. It has been shown however, that specific IgE levels tend to 
change over time and have to be interpreted along with the constellation of other 
clinical and laboratory variables and patient history to reach a diagnosis.32,33 SPTs 
are often laborious and time consuming as the full investigation may take up to 72 h 
to complete. Furthermore, subcutaneous injection of the antigen will induce swelling, 
itching and reddening at the site of injection in an allergic person and is as such a 
source of discomfort to the patient. The SPTs can be subjective for the attending 
clinician and open to interpretation as some suggest a wheal diameter of > 3 mm 
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while others recommend a diameter of > 4 mm for a positive result.32 Accumulating 
reports have shown striking differences in individual patients between SPT and 
serology test results suggesting an important role for the effector cells of immediate 
hypersensitivity (mast cells and basophils) and their activation during an allergic 
response.32,34–37 Therefore, there is a great need for a reliable in vitro method to 
complement the routine laboratory tests for sensitization/allergy when the latter show 
discrepancies or are not feasible.33 Of note, Af-specific IgE levels correlated 
significantly with CD203c levels (Supporting Figure E7). The BAT is a specific and 
reliable measure of IgE-dependent response in sensitized individuals because (i) the 
mast cells are tissue-bound, (ii) the ease of basophil accessibility and (iii) the fact that 
the upregulation of basophil surface markers can be conveniently measured by flow 
cytometry. By comparing CD203c levels to the already established cut-off sIgE value 
of 0.35 kUa/L16 to distinguish between sensitized and non-sensitized individuals, 
ROC curve analysis further confirmed the usefulness of the BAT as an indicator of Af 
sensitization in CF. Persistent and prolonged exposure to the fungus is a significant 
risk factor for Af-sensitization as sensitized patients display a higher frequency of Af 
isolation from sputum culture. Although a study by Baxter et al.15 showed no 
correlation between Af colonization and sensitization, it is conceivable that these 
different outcomes may be related to methodological differences in defining Af 
sensitization, colonization and the microbiological techniques employed. 
Interestingly, the Af-sensitized ABPA cohort had higher Af-stimulated CD203c values 
than Af-sensitized patients without ABPA illustrating that levels of measured CD203c 
may allow differentiation between Af-sensitization and CF-ABPA.  
We and others have previously shown that persistent carriage of Af in the CF airway 
is associated with radiological abnormalities, including more severe bronchiectasis 
and mosaic pattern perfusion and has an impact on pulmonary function.16,38 Af 
sensitization is also associated with lung function decline and increased duration of 
intravenous antibiotic treatments.15,17 In line with this, our data illustrate a significant 
inverse correlation between Af-stimulated CD203c values with FEV1 and BMI. These 
findings are in concordance with previously published studies suggesting a negative 
impact of Af sensitization in CF.15–17 Af sensitization likely facilitates CF-ABPA and 
multiple factors, including degree of fungal exposure, mucus viscosity, immune 
status, atopy and age may also have interdependent roles.12,32,39 Other factors, such 
as HLA-DR/HLA-DQ subtypes and the presence of single nucleotide polymorphisms 
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in the IL-4 binding site of IL-4 receptor alpha have also been described to associate 
with development of ABPA.40–42 Longitudinal studies are needed to confirm that Af 
sensitization routinely precedes ABPA.  
Baxter et al.11 have recently proposed a novel classification of aspergillosis in adult 
CF. Using a combination of serologic (total IgE, Af sIgE and sIgG), RT-PCR, and 
galactomannan (GM) data, they distinguish between non-diseased, CF-ABPA, Af 
sensitization and Af bronchitis. In accordance with their findings, we found that CF 
patients with ABPA had higher total IgE and Af sIgE levels compared to non-
sensitized and Af-sensitized patients without ABPA. Our study showed no difference 
in sIgG levels between PWCF with or without ABPA. Additionally, when applied to 
our CF population, both the GM assay and RT-PCR for Af detected a high number of 
Af-positive sputum samples (data not shown), preventing adequate differentiation 
between the cohorts according to the aforementioned classification. This high 
positivity may be due to the fact that RT-PCR identifies both live and dead 
organisms,15 and that GM assays can yield false-positive results in the presence of 
penicillin-derived antibiotics, to which many of our patients with CF are exposed.43,44 
This limits its utility in the current study.  
For the purposes of the current study, we adopted a novel, simplified classification 
that allows differentiation between non-sensitized, Af-sensitized and CF-ABPA. We 
employed a combination of Af-stimulated CD203c, total IgE and Af sIgE levels (Table 
I) to identify ABPA, avoiding the need for RT-PCR, GM or Af sIgG testing that is not 
always accessible in CF centers. Elevated Af-stimulated CD203c values (> 1.36) 
combined with elevated serum sIgE (> 1.45 kUa/L) and total IgE (> 185 kU/L) 
correctly identified all cases of CF-ABPA by the consensus conference criteria. Of 
note, the sIgE cut-off (1.45 kUa/L) used in the proposed classification system for 
identification of CF-ABPA is higher than the sIgE cut-off (0.35 kUa/L) routinely used 
to identify sensitization alone. Furthermore, the total IgE cut-off herein has been 
considerably reduced compared to consensus values used (minimum 500 kU/L) in 
line with previously published ROC-curve analysis demonstrating that the optimum 
level for ABPA diagnosis is >185 kU/L, giving 91% sensitivity and 90% specificity.11 
The inclusion of the reduced level in our proposed classification system was 
validated when one patient meeting our classification criteria for CF-ABPA, i.e. 
elevated CD203c, total IgE and Af sIgE, but not consensus conference criteria (total 
IgE > 500 kU/L), developed ABPA as defined by consensus conference criteria 
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shortly after the study conclusion. A graphical representation of our classification is 
depicted in Figure 6. 
Our previous work has shown that itraconazole alleviates fungal burden in PWCF 
colonized with Af.23 In this study, itraconazole administration did not influence Af-
stimulated CD203c levels, suggesting that fungal eradication from the lung does not 
impact Af sensitization once established. Taking into consideration that persistent Af 
colonization is a significant risk factor for sensitization, early itraconazole intervention 
may be warranted to clear colonization, reduce exposure and thereby minimize the 
risk of sensitization to Af. Acute ABPA flares can be treated with intravenously 
administered pulsed methylprednisolone at 10-15 mg/kg/day for a three day period 
every month.30,45 Methylprednisolone was administered to four CF-ABPA patients in 
this study and a trend towards reduction in Af-stimulated CD203c values was 
observed after treatment. However, this trend was not significant (P = 0.1604) 
warranting future longitudinal study with increased numbers to examine the effect of 
corticosteroid treatment on Af sensitization and potentially the use of the BAT to 
monitor treatment responses.  
In conclusion, we propose a novel and simplified means of identifying sensitization to 
Af using Af-stimulated CD203c values. Using the BAT we show that increased 
incidence of Af colonization is associated with Af sensitization and the latter state 
impacts lung function. The practical applicability of the BAT to Af in the clinical setting 
includes an evaluation of Af-stimulated CD203c values for patients positive for Af on 
at least two occasions within the preceding two years (Figure 7). If the BAT is 
negative, itraconazole treatment may be offered for fungal eradication however, a 
positive result indicates sensitization and a potential increased future risk of 
ABPA.10,16 Consequently, sensitized individuals should have their serology results 
closely monitored for increases in total IgE or Af-sIgE that may indicate  ABPA. 
Despite the lack of effect of azole treatment on the sensitization state eradication 
therapy to reduce fungal bioburden may be recommended. If sensitization is a 
prerequisite for ABPA, corticosteroids may be considered at the early sensitization 
stage to reduce the likelihood of developing ABPA. A longitudinal study with 
adequate numbers should be performed to assess the benefits of systemic 
corticosteroid administration on clinical outcomes in Aspergillus-sensitized individuals 
without ABPA.17 Timely detection of Af sensitization and CF-ABPA equips clinicians 
to deliver a targeted approach to CF-Af therapy to improve clinical outcomes. 
16 
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Tables 
 
TABLE I. Simplified classification of Aspergillus-associated disease in CF. 
 
 Af-stimulated CD203c sIgE Total IgE 
Cut-off 1.36a 1.45 kUa/Lb 185 kU/Lc 
Non-sensitized group ↓ ↓ ↓ 
Af-sensitized group ↑ ↓ ↓ 
CF-ABPA group ↑ ↑ ↑ 
aDetermined as described in the methods section. b Local cut-off value. cAs 
proposed by Baxter et al..11 
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Figure legends 
 
Figure 1. Frequency of Af-positive sputum cultures in non-sensitized PWCF 
(CF Af-sensitized-; n = 25) and Af-sensitized (CF Af-sensitized+; n = 23) in the 
two year period preceding the BAT. PWCF were screened for Af in sputum as a 
part of routine care. Data are presented as means ± standard error of mean. 
**p<0.01. 
 
Figure 2. Af-stimulated CD203c levels in non-sensitized, Af-sensitized and 
ABPA PWCF. (A) PWCF were classified as non-sensitized (n = 25) or Af-sensitized 
(n = 23). (B) The Af-sensitized cohort was further divided into those with (Af-
sensitized+ ABPA+; n=7) or without ABPA (Af-sensitized+ ABPA-; n=16). Data are 
presented as Tukey box plots and the median is represented by the middle line. 
*p<0.05, ***p<0.001. 
 
Figure 3. Correlation of Af-stimulated CD203c levels with FEV1 and BMI. Af-
stimulated CD203c levels correlated with (A) FEV1 (r
2 = 0.6409, P = 0.0002) and (B) 
BMI (r2 = 0.3009, P = 0.0278) in Af-sensitized (n = 16) but not in non-sensitized 
PWCF (FEV1; n = 25, r
2= 0.0198, P = 0.5027 and BMI; r2 = 0.0905, P = 0.1439.). 
 
Figure 4. Serologic immune parameters in PWCF according to Af sensitization 
status. (A) Total IgE, (B) sIgE and (C) sIgG serum levels were measured in non-
sensitized (n = 25), Af-sensitized (n = 16) and CF ABPA patients (n = 7). Data are 
presented as Tukey box plots and the median is represented by the middle line. 
*p<0.05, ***p<0.001. 
 
Figure 5. Effect of itraconazole treatment on Af-stimulated CD203c levels in 
PWCF. Af-stimulated CD203c levels in blood basophils from PWCF before and after 
6 weeks of treatment with oral itraconazole (n = 8, P = 0.4028) are presented as 
Tukey box plots and the line in the middle of the box represents the median. 
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Figure 6. Graphical representation of a simplified classification of Aspergillus-
associated disease using a combination of Af-stimulated CD203c, total IgE and 
sIgE levels. The blue, red and green dots denote non-sensitized (n=25), Af-
sensitized (n=16) and PWCF with ABPA (n=7), respectively as depicted with 3D 
scatter plot. 
 
Figure 7. A schematic diagram illustrating the potential stages of Aspergillus-
associated CF disease with detection methods and possible treatment 
interventions at each stage. Solid and hashed lines represent established and 
suggested treatment regimens, respectively.  
27 
 
Figures 
 
 
Figure 1.  
28 
 
 
 
 
Figure 2.  
29 
 
 
 
 
Figure 3.  
30 
 
 
 
 
 
Figure 4. 
31 
 
 
 
 
Figure 5.  
32 
 
 
 
 
 
 
 
Figure 6. 
33 
 
 
 
 
Figure 7. 
 
 
